月旦知識庫
 
  1. 熱門:
 
首頁 臺灣期刊   法律   公行政治   醫事相關   財經   社會學   教育   其他 大陸期刊   核心   重要期刊 DOI文章
護理雜誌 本站僅提供期刊文獻檢索。
  【月旦知識庫】是否收錄該篇全文,敬請【登入】查詢為準。
最新【購點活動】


篇名
運用實證探討口服麩醯胺對癌症病人接受化學治療引起的周邊神經病變之成效
並列篇名
Effect of Oral Glutamine on Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: An Evidence-Based Appraisal
作者 孫婉娜蘇靖幃申子蘋許心恬
中文摘要
背景:化學治療造成周邊神經病變(chemotherapy-induced peripheral neuropathy, CIPN),嚴重時須減少或停止化療藥物劑量及療程。針對CIPN治療方式無明確指引,口服麩醯胺(glutamine)為方法之一,但價格高且成效及劑量不明確。 目的:確認口服glutamine在CIPN成效。方法:依據PICO(population-intervention-comparison-outcome)的方式來詮釋問題,P為接受化療癌症病人;I為麩醯胺、左旋麩胺酸;C為一般照護;O為緩解、減少或改善CIPN,於Cochrane、 CINAHL、PubMed資料庫檢索,藉實證手法評析三篇隨機分派臨床實驗及兩篇類實驗性研究設計, 並進行成果測量統合分析。 結果:有四篇研究劑量為30克/天,使用時間點為化療開始時或化療後24小時內,時間最短為四天,最長 則連續一至兩個月。glutamine組與對照組在疼痛發生risk ratio = 0.26(95% CI [0.09, 0.70], Z = 2.65, p = .008),顯示glutamine組較對照組少發生疼痛且達顯著差異,而CIPN嚴重度等級、麻木感及肌肉無力在兩組則無明顯差異。從經濟效益來看,病人使用glutamine一天需額外負擔五百元費用,花費高。 結論:實務應用 由於樣本數小,結果呈現疼痛有改善,但費用增加及風險危害未顯著降低,故不主動建議化療病人為預防或改善CIPN症狀而使用口服glutamine。
英文摘要
Background: Chemotherapy may induce peripheral neuropathy, which often results in the chemotherapy dose being reduced or the chemotherapy regimen being stopped. At present, there are no treatment guidelines for chemotherapyinduced peripheral neuropathy. Glutamine is one of the treatment strategies currently applied in practice. This strategy is expensive and lacks clear evidence as to its efficacy. Purpose: To evaluate the effect of oral glutamine on CIPN in cancer patients. Methods: PICO (population- intervention- comparison- outcome) was used to focus the problem: P: cancer patient; I: glutamine, L-glutamine; C: usual care; O: alleviate, reduce, improve, and prevent. Databases searched included Airiti Library, Cochrane Library, CINAHL, and PubMed. Three randomized clinical trials and two quasi-experimental designs were evaluated using evidence-based appraisal. Results: Four studies used 30 g/day of glutamine either at the beginning of chemotherapy or at 24 hours after the beginning of chemotherapy. The shortest duration for taking glutamine was four days and longest duration was two months. The incidences of CIPN-induced pain were significantly different (risk ratio = 0.26; 95% CI [0.09, 0.70], Z = 2.65, p = .008) between the intervention and control groups. The incidences of CIPN grading, numbness, and muscle weakness were not significantly different between the intervention and control groups. From an economic point of view, the clinical efficacy of taking glutamine does not justify the additional daily cost to the patient of NT$500 (about US$17). Conclusions/Implications for Practice: Because of the small sample size, minimal effects of glutamine, and no significant decrease in risk, we do not suggest routinely using oral glutamine to prevent or reduce CIPN symptoms in cancer patients.
起訖頁 61-69
關鍵詞 麩醯胺化學治療造成周邊神經病變實證評價glutaminechemotherapy-induced peripheral neuropathyevidence-based appraisal
刊名 護理雜誌  
期數 201802 (65:1期)
出版單位 臺灣護理學會
該期刊-上一篇 職場霸凌與女性護理師照護病人安全態度之相關性探討
該期刊-下一篇 被動式音樂應用在疑似或確診癌症病人診斷性切片檢查及手術之疼痛緩解──系統性文獻回顧與統合分析
 

新書閱讀



最新影音


優惠活動




讀者服務專線:+886-2-23756688 傳真:+886-2-23318496
地址:臺北市館前路28 號 7 樓 客服信箱
Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄